Review Article

Genetic and Biological Effects of ICAM-1 E469K Polymorphism in Diabetic Kidney Disease

Xiuli Zhang1, Norhashimah Abu Seman, Henrik Falhammar3,4, Kerstin Brismar,3 and Harvest F. Gu5

1Department of Nephrology, The second People’s Hospital, Shenzhen, The first Affiliated Hospital of Shenzhen University, Guangdong 518000, China
2Cardiovascular, Diabetes and Nutrition Research Center, Institute for Medical Research, Kuala Lumpur 50588, Malaysia
3Rolf Luft Research Center for Diabetes and Endocrinology, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm 17176, Sweden
4Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm 17176, Sweden
5Center for Pathophysiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China

Correspondence should be addressed to Xiuli Zhang; zhangxiuli54321@sina.com and Harvest F. Gu; feng.gu@cpu.edu.cn

Received 10 March 2020; Accepted 22 May 2020; Published 15 June 2020

Guest Editor: Markus Wallner

Copyright © 2020 Xiuli Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Diabetic kidney disease (DKD) is a complex disease, in which local inflammatory stress results from both metabolic and hemodynamic derangements. Intercellular adhesion molecule 1 (ICAM-1) is a 90 kD acute-phase protein marker of inflammation. In the recent years, clinical observations have reported that increased serum/plasma ICAM-1 levels are positively correlated with albuminuria in the patients with type 1 (T1D) and type 2 diabetes (T2D). Genetic association studies have demonstrated that genetic polymorphisms, including SNP rs5498 (E469K, G/A), in the ICAM1 gene is associated with DKD. rs5498 is a nonsynonymous SNP and caused by substitution between E (Glu) and K (Lys) for ICAM-1 protein. In this review, we first summarized the genetic effects of ICAM1 E469K polymorphism in DKD and then demonstrated the possible changes of ICAM-1 protein crystal structures according to the genotypes of this polymorphism. Finally, we discussed the genetic effects of the ICAM1 E469K polymorphism and the biological role of increased circulating ICAM-1 protein and its formation changes in DKD.

1. Introduction

Diabetes has become a global epidemic and a large proportion of diabetes patients develop microvascular complications. Diabetic kidney disease (DKD) is a prevalent microvascular complication and presents in approximately 25–40% of patients with long-standing diabetes [1, 2]. This complication is characterized with progressive proteinuria from microalbuminuria to persistent proteinuria and confers additional risk of cardiovascular disease and mortality. DKD is the leading global cause of end-stage renal disease, a condition which requires treatment with dialysis or kidney transplantation [2, 3]. The treatment costs of patients with DKD are increasing and impose a substantial burden on the healthcare system. However, as is the case with the majority of complex diseases, identifying causal genetic variants contributing to DKD has proven difficult. A better understanding of the heritable genetic factors underlying DKD by using not only genetic studies but also biological functional analysis may lead to the discovery of new biomarkers of disease susceptibility and novel therapeutic strategies.

Although the pathogenesis in DKD is multifactorial, local inflammatory stress results from both metabolic and hemodynamic derangements [4, 5]. Intercellular adhesion molecule 1 (ICAM-1, OMIM: 147840) is a 90 kD acute-phase protein marker of inflammation. It is an inducible surface glycoprotein expressed in leukocytes, endothelial, and other cell types that promotes adhesion in immunological and inflammatory
reactions [4–6]. To better understand the genetic and biological effects of ICAM-1 in DKD, we have performed the genetic studies of the ICAM1 gene in Swedish patients with type 1 diabetes (T1D) and also in Malays type 2 diabetes (T2D) with or without DKD [7, 8]. According to the genotypes of ICAM1 genetic polymorphisms, we have analyzed the crystal structures of ICAM-1 protein by using the molecular graphics program PyMol [9–11]. In this article, we focused on the evaluation of the genetic effects of the ICAM1 E469K polymorphism in DKD and also demonstrated the possible biological changes of ICAM-1 protein crystal structure according to the genotypes of this polymorphism. Based upon that, we summarized the genetic and biological effects of the ICAM1 E469K polymorphism in DKD, which may provide useful information for better understanding the pathophysiology of the disease.

1.1. The ICAM1 Gene and Its E469K Polymorphism in DKD.

The ICAM1 gene locates to chromosome 19p13.2 in human. Genetic linkage analyses in T1D, T2D, and DKD have indicated that this chromosomal segment resides in a region linked to diabetes. Based upon a genome-wide scan study in 93 affected sib-pairs and 263 multiplex families from the UK, Mein et al. reported that a chromosomal region of 19p13 was linked to T1D [12]. Later on, this link with T1D in chromosome 19p13 was replicated by the study of 2658 affected sib-pairs in the USA [13]. The chromosomal region of 19p13 was also found to be linked with several lipid-related traits, including total cholesterol, triglycerides, and low-density lipoprotein in T2D according to the studies of Caucasian, African-American, and Hispanic families [14–16]. All these studies demonstrated that the loci in chromosome 19p13 might confer the susceptibility to diabetes and diabetic vascular complications. Interestingly, there are several genes, including INSIR (Insulin receptor), RETN (Resistin), and ICAM1, located in this chromosomal region.

In 2006, we performed a genetic association study of the ICAM1 gene in Swedish subjects with normal glucose tolerance (NGT), T1D with, or without DKD. Six single nucleotide polymorphisms (SNPs), including three Tag SNPs rs5498 (E469K A/G), rs1799969 (R241G, A/G), and rs281432 (C/G), in the ICAM1 gene were selected for genotyping experiments based upon the information of their position and function in dbSNP. The SNP rs5498 is a nonsynonymous SNP and caused by substitution between GAG for E (Glu) and AAG for K (Lys) in the 469th codon of ICAM-1 protein (position 10285007 of chromosome 19, contig ID NT_011295.12, from the version of GRCh38.p7). The ICAM1 gene consists of 7 exons and the E469K polymorphism is located in the 6th one [6, 17]. There is high linkage disequilibrium (LD) in the gene region covering exons 5 and 6 but LD from promoter to intron 4 is low. The 7th exon has a large 3′-UTR. Genotyping experiments were conducted with a high-throughput SNP scoring technique called dynamic allele-specific hybridization (DASH) [18], which was the first genotyping protocol that we have used in our laboratory. Results showed that there was a significant association of SNP rs5498 (E469K) in the ICAM1 gene between the subjects with NGT and T1D patients in Swedish population. Further analysis between T1D with and without DKD indicated that this polymorphism was associated with DKD. Interestingly, we found a high heterozygous index of this polymorphism presenting in this population [7]. About 10 years later, we replicated the genetic association study of the ICAM1 gene in Malays T2D subjects with or without DKD, and the genotyping experiments were done by using TaqMan allelic discrimination. The high heterozygous index of ICAM1 E469K polymorphism was also found in Malays population [8]. With the extension of sample collection and follow-up study, our studied cohorts were enlarged. Thereby, we were able to further evaluate the genotyping data by using TaqMan allelic discrimination. Therefore, Figure 1 in this paper was modified from our previous publications [7, 8] and represented the genotype distribution of the ICAM1 E469K polymorphism, respectively, in Swedish T1D (Figure 1(a)) and Malays T2D subjects with or without DKD (Figure 1(b)). As seen in the figure, the frequency of heterozygous E469K genotype was higher than the frequencies of both homozygous genotypes, i.e., E469 and 469K.

Once the high heterozygous index in genotyping distribution was seen, several questions had been taken into our consideration. First, was the high heterozygous index of the ICAM1 K469E polymorphism caused by genotyping error? We replicated genotyping experiments for all Swedish subjects but using another technique named pyrosequencing [19], and the genotyping results were fully matched. Thereby, the possibility of a high heterozygous index caused by genotyping error was excluded. Second, was the high heterozygous index of the ICAM1 K469E polymorphism induced by genomic duplicons in the ICAM1 gene? Several reports of human genome analyses have demonstrated that segmental duplications (duplicons) with >90% similarity between two copies may comprise at least 5% of g.DNA in human [20–22]. If a SNP is involved into the region of duplicons, a high heterozygous index may be presented in the genotype distribution. We conducted sequencing analyses along the ICAM1 gene in the studied subjects, and no duplicated sequence in the gene region was found. Third, did the high heterozygous index of the ICAM1 E469K polymorphism exist in other populations? According to the record in HapMap, the highest genotype frequency of the ICAM1 E469K polymorphism in 226 European Caucasian individuals was heterozygous at 46.0% [23], which was similar with the genotype distribution in Swedish population, while the heterozygous frequency of the ICAM1 K469E polymorphism in Malays population was even higher (Figures 1(a) and 1(b)). Before we reported the high heterozygous index of ICAM1 E469K polymorphism [7], there were several genetic association studies of ICAM1 E469K polymorphism in Danish, Finnish, and Japanese T1D subjects [24–26]. However, the information concerning the genotype distribution of this SNP in Danish and Finnish population was unclear. By the personal communications, we found that the phenomenon of high heterozygous index of this SNP exists in all studied populations.

1.2. Circulating ICAM-1 and Its Formation Changes according to the E469K Polymorphism. DKD is a progressive disease, in
T1D and T2D patients as a result of increased urinary albumin excretion (UAE) rate and compromised renal function. The early phase of microalbuminuria could be reversed, while the reduction of renal function begins with proteinuria. Clinical observation has demonstrated that high circulating ICAM-1 levels are associated with DKD, and all caused mortality and cardiovascular morbidity in T1D patients [27, 28]. Similarly, serum/plasma ICAM-1 levels were found to be correlated with albuminuria in T2D patients [29–31]. At the same time, experimental studies with diabetic animal models have supported these clinical observations and demonstrated that serum ICAM-1 levels in streptozotocin-induced rats were increased in parallel with the elevation of UAE [32]. Furthermore, ICAM-1 was found to be overexpressed in tubular epithelial cells of kidney in T2D db/db mice and in glomeruli of diabetic rats [33, 34].

ICAM-1 proteins act as ligands and the primary receptors for ICAM-1 are integrins for mediating cell–cell interactions and signal transduction. However, ICAM-1, unlike most integrin-binding proteins, does not contain an RGD (Arg-Gly-Asp) motif to promote integrin binding but is targeted to two integrins of the β2 subunit family, i.e., leukocyte adhesion protein-1 (LFA-1) and Mac-1 (integrin, alpha M) [35, 36]. Thus, ICAM-1 has a role not only for T lymphocytes activation but also for leukocyte–endothelial cell interaction. Considering the presentation of high heterozygous index of ICAM1 E469K polymorphism, we have for several years paid attention for analysis of biochemical structure and functional changes of ICAM-1 protein according the genotypes of this polymorphism. We thus used the molecular graphics program PyMol to analyze the formation of ICAM-1 protein. ICAM-1 is composed of five immunoglobulin-like domains (D1–D5), a transmembrane domain with a Gly-X-X-Gly dimerization motif, and a cytoplasmic domain that binds ezrin-radixin-moesin family adaptors that link to the actin cytoskeleton [37–40]. D1 and D3 of ICAM-1 bind to the integrins LFA-1 and Mac-1, respectively. A substantial portion of ICAM-1 on the cell surface dimerizes by fusion of each of the two β-sheets in D4 into a super β-sheet (Yang et al. 2004). The structure of a domain 3-domain 5 (D3–D5) fragment of ICAM-1 has been revealed in both monomeric and dimeric forms (Figure 2(a)). The structure of a D1-D2 fragment of ICAM-1 reveals how the αI domain of integrin LFA-1 binds to D1 [41]. At the center of the interface, a Mg2+ ion held by the αI domain binds to an acidic residue, Glu-34, in an edge β-strand of D1 of ICAM-1. Crystal structures of ICAM-1 containing domains 3, 4, and 5 [42] (Protein Databank ID 1p53 and 2 oz4) were visualized. Residue numbering in these structures is according to the mature sequence after removal of a 27-residue signal peptide; numbering in Figures 2(a) and 2(b) follows the immature sequence consisting with the nomenclature used in genetics. The E469K polymorphism locates to domain 5 of ICAM-1. Furthermore, the E-469 sidechain in the D4-D5 crystal structure protrudes from a face of D5 that is rotated about 90° away from the dimer interface. In the K-469 polymorphism, the K sidechain will protrude in a similar direction. Sidechains in the vicinity of residue 469 are shown in Figure 2(b).
1.3. Prediction of Genetic and Biological Effects of the E469K Polymorphism in DKD. Ours and other groups have found that the ICAM1 E469K polymorphism represents a high heterozygous frequency in the genotype distribution of the studied populations [7, 8, 24–26]. This high heterozygous frequency in genotype distribution is unlikely an error due to genotyping limitation or genomic duplication. We have demonstrated that DKD subjects with heterozygous genotype have increased circulating ICAM-1 levels, indicating that the ICAM1 E469K polymorphism heterozygous is most likely involved in the pathogenesis of DKD.

To understand whether the ICAM1 E469K polymorphism heterozygous has a biochemical functional role in ICAM-1 protein, we have carried out a structural analysis. Figure 2 shows a model of the dimeric form of ICAM-1 bound to the αI domain of integrin LFA-1 reconstructed by combining two crystal structures. Glu-469 in domain 5 is shown with its sidechain atoms as spheres. The Mg$^{2+}$ ion at the center of the LFA-1/ICAM-1 binding site is shown as a silver sphere. (b) Detailed view of the region boxed in (a). Sidechains of Glu-469 and nearby residues are shown in stick representation, and Glu-469 is emphasized with thicker stick. The boundary between the G β-strand in D4 that continues into the A β-strand in D5 is shown with a dotted line in the cyan ICAM-1 monomer.

Figure 2: Structural context of the ICAM1 E469K polymorphism. The structures are shown as ribbon cartoon diagrams. (a) Model of the dimeric ICAM-1 ectodomain bound to the αI domain of integrin LFA-1 reconstructed by combining two crystal structures. Glu-469 in domain 5 is shown with its sidechain atoms as spheres. The Mg$^{2+}$ ion at the center of the LFA-1/ICAM-1 binding site is shown as a silver sphere. (b) Detailed view of the region boxed in (a). Sidechains of Glu-469 and nearby residues are shown in stick representation, and Glu-469 is emphasized with thicker stick. The boundary between the G β-strand in D4 that continues into the A β-strand in D5 is shown with a dotted line in the cyan ICAM-1 monomer.

is maintained by a continuous β-strand formed by β-strand G in D4 and A in D5. Thus, although in the ICAM-1 dimer the D4-D4 interface is extensive and the D5-D5 interface is small, the stable orientation between D4 and D5 provides confidence that the monomer-monomer interface at D5 of ICAM-1 dimers on cell surfaces. There are no significant interactions between any of the neighboring residues that would be perturbed by the polymorphism. The E469K polymorphism is therefore expected to have no effect on the equilibrium between monomeric and dimeric forms of ICAM-1 on the cell surface. The polymorphism also locates distal from the integrin-binding sites in D1 and D3 and might disrupt the protein biochemical function.

We speculate that it may affect the formation of higher-order assemblies of ICAM-1 on the cell surface. Interaction between cells bearing LFA-1 and ICAM-1 results in the clustering of ICAM-1 at sites of cell-cell adhesion. Clustering has been visualized both at immunological synapses and in “cups” that form around lymphocytes that are migrating through endothelial cells [39]. Clustering is likely to be enhanced by association of integrins with the actin cytoskeleton through adaptors such as talin and kindlin and association of ICAM-1 with the actin cytoskeleton through ezrin-radixin-moesin family members. "Strings" of ICAM-1 may form on the cell surface through dimerization of ICAM-1 both at the D4-D4 interface and a weaker D1-D1 interface [40]. We speculate that ICAM-1 strings laterally associate to form higher-order assemblies through an interface in which Glu-469 participates. Glu-469 protrudes from a relatively flat surface on D5 that bears three Thr residues of
modest hydrophobicity and the hydrophobic residue Leu-456 (Figure 2(b)) that make this face of D5 a candidate for an interface in higher-order lateral association of strings. Because Lys is opposite in charge from Glu, the polymorphism might disrupt such a lateral association. Glu-469 has no specific interactions such as hydrogen bonds with neighboring residues, so an effect on the stability of D5 or ICAM-1 of the polymorphism seems unlikely. We speculate that Glu-469 is involved in the formation of higher-order ICAM-1 assemblies on cell surfaces, an idea that requires further investigation. The question why DKD subjects heterozygous have increased circulating ICAM-1 levels still remains, although, we have demonstrated the ICAM1 E469K polymorphism has the effects in structure and biochemical functional changes of ICAM-1. It may be necessary to purify the ICAM-1 protein from serum or plasma samples of DKD subjects heterozygous for further 3D protein structural and functional analyses.

There are several reports concerning the heterozygous carriers with increased phenotypes. Previously, Leiber et al. have demonstrated that the 50% of the heterozygous carriers of MEFV mutations have increased serum concentrations of neutrophil-derived protein S100A12 [43]. Recently, Taillandier et al. have reported that the Pro549Ala heterozygous carriers of COL1A2 have more serious phenotypes of hypophosphatasia, mainly due to the dominant-negative effects [44]. Zhu et al. have identified a novel heterozygous variant, which leads to the formation of a truncated COL4A4 protein in Alport Syndrome [45]. Moreover, Serra-Juhe et al. have showed that heterozygous rare variants in several candidate genes of the melanocortin pathway have strong effects in non-syndromic severe obesity [46]. Therefore, the genetic effects of heterozygous of ICAM1 E469K and its related functional changes that we have reported in the present study may not be the findings “by chance.” Liu et al. have conducted a meta-analysis for ICAM1 E469K polymorphism and DKD in several cohorts by using allelic, dominant, recessive, and additive models. The statistically significant heterogeneity (I² ranged from 62-95) across the studies is observed [47].

Evidence from experimental studies with animal models for diabetes has indicated that ICAM-1 is overexpressed not only in glomeruli diabetic rats [48] but also in tubular epithelial cells of kidney in T2D db/db mice [49]. Figure 3 is a schematic diagram to illustrate the possible cellular mechanism of ICAM1 in the development of diabetic kidney disease. This schematic diagram implicates that ICAM1 DNA transcription in the nuclei and mRNA translation in plasma of endothelium cells is increased under a diabetic condition with hyperglycemia. Subsequently, the ICAM-1 protein expression on the surface of endothelium cells is upregulated. ICAM-1 protein binding activity with leukocyte adhesion protein-1 (LEA-1), which is from blood, is increased, while heterozygous of ICAM1 E469K protein likely more actively binds with LFA-1. Thereby, more and more lymphocytes from blood due to combining ICAM-1 and IFA-1 are transferred through endothelium cells in glomeruli and peritubular capillaries of the nephron in the kidney. Consequently, injury of kidney glomeruli and tubular has occurred.

1.4. Summary and Perspective. Taking together the evidence from genetic studies and biochemical functional analyses, we propose that the heterozygous carriers of the ICAM1 E469K polymorphism among the patients with DKD have increased circulating ICAM-1 protein, while the formation of ICAM-1 protein and related biological function are changed. ICAM-1 plays a pathophysiological role in the development of DKD as previously described [6]. Under a diabetic condition with hyperglycemia, the ICAM1 gene transcription in the nuclei is increased and expression on the surface of endothelium cells is upregulated. ICAM-1 protein binding activity with leukocyte adhesion protein-1 (LFA-1) is increased and more lymphocytes from blood are transferred into cells of glomeruli and peritubular capillaries of the nephron in the kidney. Clinically, serum/plasma ICAM-1 levels are found to be increased and the proteins are released to urine, while injury in kidney glomeruli and tubular has occurred. Therefore, we suggest that heterozygosity of the ICAM1 E469K polymorphism may confer an increased risk susceptibility in DKD.

Although the additional information concerning the genetic and biological effects of ICAM-1 in DKD in this article has been provided, there are still several questions remained. For instance, what are “the ICAM-1 protein molecular structure and biological function per see” in serum/plasma of DKD subjects with the ICAM1 E469K heterozygous genotype? How does ICAM-1 heterozygous protein bind with LFA-1 with higher activity and subsequently induces more lymphocytes transferred from blood into the cells of glomeruli and peritubular capillaries of the nephron in the kidneys? Further investigation to address these questions has been taken into our consideration.

Conflicts of Interest

The authors declare that they have no conflicts of interest.
Acknowledgments

The authors wish to thank Professor Timothy A. Springer from Harvard Medical School, USA, and Dr. Björn Andersstam from Karolinska University Hospital, Sweden, for their excellent guideline and valuable discussion in the crystal structure and plasma/serum levels of ICAM-1 protein.

References

[1] International Diabetes Federation, *Diabetes Atlas*, International Diabetes Federation, Brussels, 7th ed edition, 2015.
[2] A. Levin, M. Tonelli, J. Bonventre et al., "Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy," *Lancet*, vol. 390, no. 10105, pp. 1888–1917, 2017.
[3] A. S. Krolewski, J. Skupien, P. Rossing, and J. H. Warram, "Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes," *Kidney International*, vol. 91, no. 6, pp. 1300–1311, 2017.
[4] J. F. Navarro-González, C. Mora-Fernández, M. M. de Fuentes, and J. García-Pérez, "Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy," *Nature Reviews Nephrology*, vol. 7, no. 6, pp. 327–340, 2011.
[5] R. Pichler, M. Afkarian, B. P. Dieter, and K. R. Tuttle, "Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets," *American Journal of Physiology-Renal Physiology*, vol. 312, no. 4, pp. F716–F731, 2017.
[6] H. F. Gu, J. Ma, K. T. Gu, and K. Brismar, "Association of intercellular adhesion molecule 1 (ICAM1) with diabetes and diabetic nephropathy," *Frontiers in Endocrinology*, vol. 3, 2013.
[7] J. Ma, A. Möllsten, M. Prázny et al., "Genetic influences of the intercellular adhesion molecule 1 (ICAM-1) gene polymorphisms in development of Type 1 diabetes and diabetic nephropathy," *Diabetic Medicine*, vol. 23, no. 10, pp. 1093–1099, 2006.
[8] N. Abu Seman, B. Anderstam, W. N. Wan Mohamud, C. G. Östenson, K. Brismar, and H. F. Gu, "Genetic, epigenetic and protein analyses of intercellular adhesion molecule 1 in Malaysian subjects with type 2 diabetes and diabetic nephropathy," *Journal of Diabetes Research*, vol. 29, no. 8, pp. 1234–1239, 2015.
[9] A. Arroyuelo, J. A. Vila, and O. A. Martin, "Azahar: a PyMOL plugin for construction, visualization and analysis of glycan molecules," *Journal of Computer-Aided Molecular Design*, vol. 30, no. 8, pp. 619–624, 2016.
[10] S. Yuan, H. C. S. Chan, S. Filippek, and H. Vogel, "PyMOL and Inkscape bridge the data and the data visualization," *Structure*, vol. 24, no. 12, pp. 2041–2042, 2016.
[11] Schrodingerhttps://www.schrodinger.com/pymol.
[12] C. A. Mein, L. Esposito, M. G. Dunn et al., "A search for type 1 diabetes susceptibility genes in families from the United Kingdom," *Nature Genetics*, vol. 19, no. 3, pp. 297–300, 1998.
[13] P. Concannon, W. M. Chen, C. Julier et al., "Genome-wide scan for linkage to type 1 diabetes in 2,496 multiplex families from the type 1 diabetes genetics consortium," *Diabetes*, vol. 58, no. 4, pp. 1018–1022, 2009.
[14] G. Imperatore, W. C. Knowler, D. J. Pettitt, S. Kobes, P. H. Bennett, and R. L. Hanson, "Segregation analysis of diabetic nephropathy in Pima Indians," *Diabetes*, vol. 49, no. 6, pp. 1049–1056, 2000.
[15] A. Malhotra, J. K. Wolford, and the American Diabetes Association GENNID Study Group, "Analysis of quantitative lipid traits in the genetics of NIDDM (GENNID) study," *Diabetes*, vol. 54, no. 10, pp. 3007–3014, 2005.
[16] A. A. Adeyemo, T. Johnson, J. Acheampong et al., "A genome wide quantitative trait linkage analysis for serum lipids in type 2 diabetes in an African population," *Atherosclerosis*, vol. 181, no. 2, pp. 389–397, 2005.
[17] https://www.ncbi.nlm.nih.gov/snp/rs5498/.
[18] W. M. Howell, M. Jobs, U. Gyllensten, and A. J. Brookes, "Dynamic allele-specific hybridization. A new method for scoring single nucleotide polymorphisms," *Nature Biotechnology*, vol. 17, no. 1, pp. 87–88, 1999.
[19] M. Ronaghi, M. Uhlen, and P. Nyrén, "A sequencing method based on real-time pyrophosphate," *Science*, vol. 281, no. 5375, pp. 363–365, 1998.
[20] J. C. Venter, M. D. Adams, E. W. Myers et al., "The sequence of the human genome," *Science*, vol. 291, no. 5507, pp. 1304–1351, 2001.
[21] D. Fredman, S. J. White, S. Potter, E. E. Eichler, J. T. D. Dunn, and A. J. Brookes, "Complex SNP-related sequence variation in segmental genome duplications," *Nature Genetics*, vol. 36, no. 8, pp. 861–866, 2004.
[22] Z. Cheng, M. Ventura, X. She et al., "A genome-wide comparison of recent chimpanzee and human segmental duplications," *Nature*, vol. 437, no. 7055, pp. 88–93, 2005.
[23] https://www.ncbi.nlm.nih.gov/variation/news/ncbi_retiring_HapMap/.
[24] O. P. Kristiansen, R. L. Nolte, H. Holst et al., "The intercellular adhesion molecule-1 K469E polymorphism in type 1 diabetes," *Immunogenetics*, vol. 52, no. 1–2, pp. 107–111, 2000.
[25] S. Nejentsev, A. P. Laine, O. Simell, and J. Ilonen, "Intercellular adhesion molecule-1 (ICAM-1) K469E polymorphism: no association with type 1 diabetes among Finns," *Tissue Antigens*, vol. 55, no. 6, pp. 568–570, 2000.
[26] M. Nishimura, H. Obayashi, E. Maruya et al., "Association between type 1 diabetes age-at-onset and intercellular adhesion molecule-1 (ICAM-1) gene polymorphism," *Human Immunology*, vol. 61, no. 5, pp. 507–510, 2000.
[27] J. Lin, R. J. Glynn, N. Rifai et al., "Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial," *Diabetes Care*, vol. 31, no. 12, pp. 2338–2343, 2008.
[28] A. S. Astrup, L. Tarnow, L. Pietraszek et al., "Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate," *Diabetes Care*, vol. 31, no. 6, pp. 1170–1176, 2008.
[29] A. Becker, V. W. M. van Hinsbergh, A. Jager et al., "Why is soluble intercellular adhesion molecule-1 related to cardiovascular mortality?*, *European Journal of Clinical Investigation*, vol. 32, no. 1, pp. 1–8, 2002.
[30] A. F. Rubio-Guerra, H. Vargas-Robles, G. V. Ayala, and B. A. Escalante-Acosta, "Correlation between circulating adhesion molecule levels and albuminuria in type 2 diabetic normotensive patients," *Medical Science Monitor*, vol. 13, no. 8, pp. CR349–CR352, 2007.
[31] K. Sahakyan, B. E. K. Klein, K. E. Lee, M. Y. Tsai, and R. Klein, "Inflammatory and endothelial dysfunction markers and proteinuria in persons with type 1 diabetes mellitus," *European Journal of Endocrinology*, vol. 162, no. 6, pp. 1101–1105, 2010.
[32] Y. Qian, S. Li, S. Ye et al., "Renoprotective effect of rosiglitazone through the suppression of renal intercellular adhesion molecule-1 expression in streptozotocin-induced diabetic rats," *Journal of Endocrinological Investigation*, vol. 31, no. 12, pp. 1069–1074, 2008.

[33] T. Kosugi, T. Nakayama, M. Heinig et al., "Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice," *American Journal of Physiology-Renal Physiology*, vol. 297, no. 2, pp. F481–F488, 2009.

[34] N. Watanabe, K. Shikata, Y. Shikata et al., "Involvement of MAPKs in ICAM-1 expression in glomerular endothelial cells in diabetic nephropathy," *Acta Medica Okayama*, vol. 65, no. 4, pp. 247–257, 2011.

[35] A. van de Stolpe, N. Jacobs, W. J. Hage et al., "Fibrinogen binding to ICAM-1 on EA.hy 926 endothelial cells is dependent on an intact cytoskeleton," *Thrombosis and Haemostasis*, vol. 75, no. 1, pp. 182–189, 1996.

[36] C. A. Janeway Jr., "How the immune system works to protect the host from infection: a personal view," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 13, pp. 7461–7468, 2001.

[37] D. E. Staunton, M. L. Dustin, H. P. Erickson, and T. A. Springer, "The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and rhinovirus," *Cell*, vol. 61, no. 2, pp. 243–254, 1990.

[38] P. L. Reilly, J. R. Woska, D. D. Jeanfavre, E. McNally, R. Rothlein, and B. J. Bormann, "The native structure of intercellular adhesion molecule-1 (ICAM-1) is a dimer. Correlation with binding to LFA-1," *Journal of Immunology*, vol. 155, no. 2, pp. 529–532, 1995.

[39] O. Barreiro, M. Yáñez-Mó, J. M. Serrador et al., "Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes," *The Journal of Cell Biology*, vol. 157, no. 7, pp. 1233–1245, 2002.

[40] Y. Yang, C. D. Jun, J. H. Liu et al., "Structural basis for dimerization of ICAM-1 on the cell surface," *Molecular Cell*, vol. 14, no. 2, pp. 269–276, 2004.

[41] M. Shimaoka, T. Xiao, J. H. Liu et al., "Structures of the alpha L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation," *Cell*, vol. 112, no. 1, pp. 99–111, 2003.

[42] X. Chen, T. D. Kim, C. V. Carman, L. Z. Mi, G. Song, and T. A. Springer, "Structural plasticity in Ig superfamily domain 4 of ICAM-1 mediates cell surface dimerization," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 39, pp. 15358–15363, 2007.

[43] M. Lieber, T. Kallinich, P. Lohse et al., "Increased serum concentrations of neutrophil-derived protein S100A12 in heterozygous carriers of MEFV mutations," *Clinical and Experimental Rheumatology*, vol. 33, 6 Suppl 94, pp. S113–S116, 2015.

[44] A. Taillandier, C. Domingues, A. Dufour et al., "Genetic analysis of adults heterozygous for ALPL mutations," *Journal of Bone and Mineral Metabolism*, vol. 36, no. 6, pp. 723–733, 2018.

[45] F. Zhu, W. Li, Z. Li, H. Zhu, and J. Xiong, "Identification of a Novel COL4A4 Variant in Compound-Heterozygous State in a Patient with Alport Syndrome and Histological Findings Similar to Focal Segmental Glomerulosclerosis (FSGS)," *Frontiers in Genetics*, vol. 9, 2019.

[46] C. Serra-Juhé, G. Á. Martos-Moreno, F. Bou de Pieri et al., "Heterozygous rare genetic variants in non-syndromic early-onset obesity," *International Journal of Obesity*, vol. 44, no. 4, pp. 830–841, 2020.

[47] L. Liu, D. He, L. Fang, and X. Yan, "Association between E469K polymorphism in the ICAM1 gene and the risk of diabetic nephropathy: a meta-analysis," *Lipids in Health and Disease*, vol. 17, no. 1, p. 293, 2018.